文献速递头颈部肿瘤放疗

复发头颈鳞癌再程放疗:术后与根治性IMRT的系统综述与Meta分析

Challenges in recurrent head and neck squamous cell cancer treatment: systematic review and meta-analysis comparing efficacy and toxicity between post-operative and definitive IMRT-based reirradiation.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-10-25

该系统综述与Meta分析比较了复发头颈鳞癌再程放疗中术后IMRT与根治性IMRT的疗效与安全性。纳入10项研究共958例患者,术后IMRT组1年总生存率68%显著优于根治性IMRT组的55%(RR 0.84,95%CI 0.76-0.93),1年局部区域控制率也显著更优(65% vs 58%,RR 0.89,95%CI 0.798-0.997),但证据确定性低,放射性毒性报告不足。

要点

  • 术后IMRT再程放疗1年总生存率68%,显著优于根治性IMRT的55%。
  • 术后IMRT组1年局部区域控制率65%,显著优于根治性IMRT的58%。
  • 放射性毒性报告不足,无法得出结论;证据确定性低。

核心结论

  • 术后IMRT再程放疗获得更优的生存和肿瘤控制,应作为适合手术患者的首选方案。
  • 仔细的患者评估和筛选是最大化疗效并最小化治疗相关毒性的基础。

研究设计与样本

  • 系统检索MEDLINE、Cochrane Library、Web of Science、SCOPUS和PsycINFO,采用Newcastle-Ottawa量表评估偏倚风险。
  • 纳入10项合格研究,共958例患者,其中仅2项为前瞻性试验;中位随访24.9个月(范围9.6-78.1)。
  • 术后/辅助IMRT组455例,根治性IMRT组503例;中位年龄62岁(范围48-63),男性占78%,同步全身治疗比例在0至100%之间变化。
  • 采用随机效应模型进行Meta分析。

主要发现

  • 术后IMRT组1年总生存率为68%,根治性IMRT组为55%,风险比(RR)0.84(95%CI 0.76-0.93)。
  • 术后IMRT组1年局部区域控制率为65%,根治性IMRT组为58%,RR 0.89(95%CI 0.798-0.997)。
  • 所有其他终点均未达到统计学显著性。
  • 由于纳入研究的局限性,上述发现的证据确定性为低。
  • 放射性毒性报告不足,无法得出任何结论。

关键数值与推荐

  • 术后IMRT组1年总生存率68% vs 根治性IMRT组55%,RR 0.84(95%CI 0.76-0.93)。
  • 术后IMRT组1年局部区域控制率65% vs 根治性IMRT组58%,RR 0.89(95%CI 0.798-0.997)。

临床怎么用

  • 对于可手术的复发头颈鳞癌患者,术后IMRT再程放疗应作为首选方案。
  • 治疗前需仔细评估和筛选患者,以最大化疗效并最小化治疗相关毒性。
  • 由于放射性毒性数据不足,临床决策中应关注毒性管理并积累相关证据。

局限性

  • 纳入研究存在局限性,导致证据确定性低。
  • 仅2项为前瞻性试验,多数为回顾性研究。
  • 放射性毒性报告不足,无法对安全性得出结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Treatment of patients with recurrent head and neck squamous cell cancer in a previously irradiated field remains challenging. We performed a meta-analysis, comparing the efficacy and safety of definitive and post-operative intensity-modulated radiotherapy (IMRT) based reirradiation. MATERIAL AND METHODS: MEDLINE, Cochrane Library, Web of Science, SCOPUS and PsycINFO were systematically searched. The Newcastle-Ottawa Scale was used to assess the risk of bias. A meta-analysis was performed using the random-effects model. RESULTS: 10 eligible studies with a median follow up of 24.9 months (9.6-78.1) and a total of 958 patients were identified, two of which are prospective trials. 455 were patients treated with post-operative/ adjuvant IMRT (aIMRT), while 503 patients received definitive IMRT (dIMRT). Median age was 62 years (48-63), 78 % were males and the rate of concomitant systemic therapy varied between 0 and 100 %.Post-operative IMRT showed significantly higher 1-year overall survival of 68 %, compared to 55 % for dIMRT, with a risk reduction (RR) of 0.84 (95 % CI: 0.76-0.93). aIMRT achieved superior 1-year locoregional control (65 %) in comparison to dIMRT (58 %) with an RR of 0.89 (95 % CI: 0.798 to 0.997). All other endpoints did not reach statistical significance. The certainty of our findings was low, due to limitations in the included studies. Radiotoxicity was insufficiently reported and does not allow any conclusions. CONCLUSION: Post-operative IMRT achieves superior survival and tumor control and should be the preferred option for patients eligible for surgery. Careful patient evaluation and selection are fundamental to maximizing therapeutic efficacy while minimizing treatment-related toxicities.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Grajewski L, Greiner A, Wurschi G, et al. Challenges in recurrent head and neck squamous cell cancer treatment: systematic review and meta-analysis comparing efficacy and toxicity between post-operative and definitive IMRT-based reirradiation. Clin Transl Radiat Oncol. 2025. PMID: 41281631. doi:10.1016/j.ctro.2025.101061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。